Atezolizumab in the treatment of small cell lung cancer

Atezolizumab in the treatment of small cell lung cancer

Small cell lung cancer (SCLC) remains one of the most aggressive cancers, with a high relapse rate and limited treatment outcomes. The introduction of immunotherapy, including PD-L1 inhibitors such as atezolizumab and durvalumab, has changed the standard of care, especially in advanced-stage diseas...

Full description

Saved in:
Bibliographic Details
Main Authors: Kacper Ordon, Karolina Skonieczna, Olimpia Wiciun, Magdalena Badziąg, Paulina Szulc, Laura Kurczoba, Martyna Kłossowska, Olga Kądziołka
Format: Article
Language:English
Published: Nicolaus Copernicus University in Toruń 2025-06-01
Series:Quality in Sport
Subjects:
Small cell lung cancer (SCLC), Immunotherapy, Atezolizumab, Durvalumab, Lurbinectidine, Biomarker-driven therapies, Chemoradiotherapy, Targeted therapies
Online Access:https://apcz.umk.pl/QS/article/view/60497
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items